A Ranibizumab Ocular Implant (Susvimo) for Age-Related Macular Degeneration
Date: May 2, 2022
Issue #:
1649Summary:
The FDA has approvedSusvimo (Genentech), a
refillable permanent ocular implant containing the
vascular endothelial growth factor (VEGF) inhibitor
ranibizumab, for treatment of neovascular (wet) age-related
macular degeneration (nAMD) in patients who
have previously responded to at least two intravitreal
injections of a VEGF inhibitor. Ranibizumab intravitreal
injection (Lucentis) has been available since 2006 for
monthly treatment of nAMD. The FDA has approved
ranibizumab-nuna (Byooviz), a biosimilar of Lucentis
and the first ophthalmologic biosimilar; it will be
available in June 2022.
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: admin Source Type: research